Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Activa Medicare Coverage Decision Favored By Tech Assessment

This article was originally published in The Gray Sheet

Executive Summary

Clinical studies evaluating bilateral deep-brain stimulation (DBS) for treatment of Parkinson's disease support improved health outcomes associated with the procedure, a BlueCross BlueShield Association technology assessment suggests

You may also be interested in...



Medtronic Activa coverage

Review of Medicare coverage for deep brain stimulation (DBS) for Parkinson's disease is slated to go before Medicare Coverage Advisory Committee's Medical and Surgical Products Panel June 12, CMS reports March 8. The decision to put the issue before the panel likely will push what was most recently an April 5 deadline for a coverage decision into August. In February, CMS released a favorable BlueCross BlueShield Association technology assessment commissioned by the agency (1"The Gray Sheet" Feb. 11, 2002, p. 7)...

Medtronic Activa coverage

Review of Medicare coverage for deep brain stimulation (DBS) for Parkinson's disease is slated to go before Medicare Coverage Advisory Committee's Medical and Surgical Products Panel June 12, CMS reports March 8. The decision to put the issue before the panel likely will push what was most recently an April 5 deadline for a coverage decision into August. In February, CMS released a favorable BlueCross BlueShield Association technology assessment commissioned by the agency (1"The Gray Sheet" Feb. 11, 2002, p. 7)...

Medtronic Activa Postmarket Study On Parkinson’s Will Begin By Summer

Medtronic's 230-patient, three-year post-approval study of its Activa Parkinson's disease neurostimulation therapy will begin enrollment by this summer

Related Content

UsernamePublicRestriction

Register

MT016093

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel